Androgenetic alopecia. Androgenetic alopecia
Conditions
Interventions
Intervention 1: Interventional group:plasma rich platelet,is uptaken from their blood after sentrifuge. Intervention 2: Control group1:take 1 miligram finastride daily. Intervention 3: Control group2:
Treatment - Other
Treatment - Drugs
Placebo
Interventional group:plasma rich platelet,is uptaken from their blood after sentrifuge
Control group1:take 1 miligram finastride daily
Control group2:apply placebo once aday on their head,placebo composed of 25% alcohol and 75% N/S
Sponsors
Vice Chancellor of Iran university of Medical science-Research committee
Eligibility
Sex/Gender
Male
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: androgenic alopecia Hamilton grade 2 and 3; 20-35 years old men;normal laboratory tests of TSH, CBC AND ferritin ; do not use oral finastride or topical minoxidil for the last 3 months.Exclusion criteria:another systemic or topical disease on the scalp;use of telogen effluvium drugs;nutritional disease;scarring alopecia)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Androgenetic alopecia. Timepoint: 3 months and 6months later. Method of measurement: Photography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hair growing. Timepoint: 3months and 6 months later. Method of measurement: Photography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Elham Behrangi
Iran University of Medical Science
Outcome results
None listed